Tag: ASCO
Bayer: to present new data at ASCO GU
(CercleFinance.com) – Bayer will present new data on its entire prostate cancer portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU), which will be held in San Francisco,…
Bayer: To present new data at ASCO GU
(CercleFinance.com) – Bayer will present new data on its entire prostate cancer portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU), which will be held in San Francisco,…
Bristol Myers:presents Opdivo treatment at ASCO GU 2024
(CercleFinance.com) – Bristol Myers Squibb presents transformative research in the treatment of genitourinary cancers at ASCO GU 2024. The group presents the first presentation of results from the phase 3…
Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023 – 06/05/2023 at 07:30
TG4001 can induce de novo immune responses against HPV16 antigens E6 and E7 in patients with advanced HPV16-positive anogenital cancers Patients with complete objective response showed strong vaccine-induced immunoreactivity Transgene…
ASCO 2023 – Transgene presents immunological data demonstrating that TG4001, an innovative therapeutic cancer vaccine, can induce immune responses against HPV16 antigens in the ongoing Phase II trial – 06/05/2023 at 07:30
TG4001 can induce de novo immune responses against HPV16 E6 and E7 antigens in patients with HPV16-positive anogenital cancers Patients with a complete clinical response also have strong immunoreactivity induced…
Novartis: Presents Leukemia Study at ASCO
(CercleFinance.com) – Novartis’ Scemblix® shows superior long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia study. Novartis presented longer-term follow-up data from the Phase III ASCEMBL study…
Novartis: Presents Leukemia Study at ASCO
(CercleFinance.com) – Novartis’ Scemblix® shows superior long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia study. Novartis presented longer-term follow-up data from the Phase III ASCEMBL study…
Nanobiotix: New attempt to rebound on the stock market for Nanobiotix, highlighted at the ASCO meeting
(BFM Bourse) – The presence of the French specialist in nanomedicine at the largest medical congress dedicated to the fight against cancer (the annual meeting of the American Society for…
Nanobiotix: well geared towards a presentation at ASCO – 06/06/2022 at 11:30 am
(CercleFinance.com) – Nanobiotix climbs 7% after the announcement of the presentation, at the annual meeting of the American Society for Clinical Oncology (ASCO), of new data highlighting the potential of…
Transgene presented new Phase I data of TG4050 at the ASCO 2022 congress – 06/06/2022 at 08:00
Strasbourg, France, June 6, 2022, 8 a.m. – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops immunotherapies based on viral vectors against cancers, announces that it has…
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 – 06/06/2022 at 08:00
Strasbourg, France, June 6, 2022, 8:00 am CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that…
Transgene: ‘Promising’ data unveiled at ASCO
Read also (CercleFinance.com) – Transgene shares are on the rise on the Paris Stock Exchange on Monday following the presentation of data deemed ‘promising’ at the annual ASCO cancer conference.…